We are live on
!
Find out more
ABI
Adamant Biomedical Investments Portfolio holdings
AUM
$418M
This Fund
S&P 500
This Quarter
Est. Return
+10.95%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$418M
AUM Growth
+$17.7M
(+4.4%)
Cap. Flow
-$20M
Cap. Flow
% of AUM
-4.77%
Top 10 Holdings %
Top 10 Hldgs %
32.81%
Holding
108
New
12
Increased
10
Reduced
35
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HSP
HOSPIRA INC
HSP
|
+$5.08M |
| 2 |
WX
WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX
|
+$4.94M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
+$4.82M |
| 4 |
MDVN
MEDIVATION, INC.
MDVN
|
+$4.68M |
| 5 |
Ligand Pharmaceuticals
LGND
|
+$4.24M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$4.8M |
| 2 |
ProShares Ultra NASDAQ Biotechnology
BIB
|
+$4.11M |
| 3 |
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
|
+$4.02M |
| 4 |
Teva Pharmaceuticals
TEVA
|
+$3.9M |
| 5 |
QGENF
QIAGEN NV
QGENF
|
+$3.53M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.28% |
| 2 | Financials | 0.93% |
| 3 | Industrials | 0.35% |
| 4 | Technology | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $20.8M | 4.98% |
186,170
-20,550
| -10% | -$2.17M |
|
2
Biogen
BIIB
$30B
| $18.1M | 4.32% |
53,250
-1,770
| -3% | -$573K |
|
3
Gilead Sciences
GILD
$162B
| $17M | 4.06% |
180,390
-16,000
| -8% | -$1.65M |
|
4
Amgen
AMGN
$198B
| $15.1M | 3.62% |
95,000
-5,000
| -5% | -$779K |
|
|
AGN
5
DELISTED
Allergan plc
AGN
| $13.3M | 3.17% |
51,590
-520
| -1% | -$130K |
|
6
UnitedHealth
UNH
$396B
| $11.6M | 2.78% |
115,000
-13,000
| -10% | -$1.23M |
|
7
Viatris
VTRS
$20.5B
| $11.3M | 2.69% |
200,000
-30,000
| -13% | -$1.61M |
|
|
CTRX
8
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
| $10.7M | 2.57% |
206,820
+70,080
| +51% | +$3.29M |
|
|
ALXN
9
DELISTED
Alexion Pharmaceuticals
ALXN
| $10.5M | 2.52% |
57,000
-3,000
| -5% | -$556K |
|
10
Medtronic
MDT
$105B
| $8.77M | 2.1% |
121,500
-28,500
| -19% | -$1.98M |
|
11
Vertex Pharmaceuticals
VRTX
$122B
| $8.67M | 2.07% |
73,000
| – | – |
|
12
Regeneron Pharmaceuticals
REGN
$70.8B
| $8.62M | 2.06% |
21,000
+3,000
| +17% | +$1.18M |
|
13
McKesson
MCK
$97B
| $8.51M | 2.03% |
41,000
| – | – |
|
|
CYTO
14
DELISTED
Altamira Therapeutics Ltd
CYTO
| $8.46M | 2.02% |
27
| – | – |
|
|
MNK
15
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $7.92M | 1.89% |
80,000
| – | – |
|
16
Abbott
ABT
$174B
| $7.79M | 1.86% |
173,000
-27,000
| -14% | -$1.18M |
|
|
AGN
17
DELISTED
Allergan Inc
AGN
| $7.44M | 1.78% |
35,000
| – | – |
|
18
Illumina
ILMN
$29.1B
| $7.38M | 1.76% |
41,120
-3,084
| -7% | -$543K |
|
|
19
Acadia Pharmaceuticals
ACAD
$4.35B
| $6.51M | 1.56% |
205,000
+170,000
| +486% | +$4.82M |
|
|
MDVN
20
DELISTED
MEDIVATION, INC.
MDVN
| $6.47M | 1.55% |
130,000
+90,000
| +225% | +$4.68M |
|
21
Cardinal Health
CAH
$53.2B
| $6.46M | 1.54% |
80,000
-25,000
| -24% | -$1.97M |
|
22
Ionis Pharmaceuticals
IONS
$8.82B
| $6.17M | 1.48% |
100,000
-40,000
| -29% | -$1.97M |
|
|
AKRX
23
DELISTED
Akorn Inc
AKRX
| $5.79M | 1.38% |
160,000
+100,000
| +167% | +$3.86M |
|
24
Eli Lilly
LLY
$1.05T
| $5.52M | 1.32% |
80,000
| – | – |
|
|
HSP
25
DELISTED
HOSPIRA INC
HSP
| $5.51M | 1.32% |
+90,000
| New | +$5.08M |
|
Similar funds
AGCJ
ACM
RNS
NTP
MMC
LOM
CAMI
NES
Adamant Biomedical Investments's Q4 2014 Portfolio in Review
As of Q4 2014, Adamant Biomedical Investments held 108 positions worth $418M, up 4.4% from $401M the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Adamant Biomedical Investments withdrew a net $20M in Q4 2014, closing 7 positions and reducing 35 holdings. Its most notable exit was Insulet, an estimated $2.95M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 87% a quarter earlier, followed by Financials and Industrials.
Against the trend, Adamant Biomedical Investments opened a new position in HOSPIRA INC worth $5.51M.
- Adamant Biomedical Investments's largest Q4 2014 buy was HOSPIRA INC: 90,000 shares worth $5.51M.
- Adamant Biomedical Investments added most to Acadia Pharmaceuticals in Q4 2014, an estimated $4.82M increase.
- Adamant Biomedical Investments's biggest Q4 2014 reduction was COVIDIEN PLC COM SHS NEW (IRELAND), cutting an estimated $4.8M.
- Adamant Biomedical Investments fully exited Insulet in Q4 2014, selling an estimated $2.95M.
- Adamant Biomedical Investments's ten largest holdings make up 33% of its $418M portfolio in Q4 2014.
- Adamant Biomedical Investments opened 12 new positions and closed 7 in Q4 2014.
- Adamant Biomedical Investments's portfolio value rose 4.4% quarter-over-quarter to $418M.
Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.